Diligence memo · auto-generated · as of July 2, 2026
Dilon Technologies Inc
Dilon Technologies Inc looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Dilon Technologies Inc operates in Biotechnology, based in NEWPORT NEWS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Dilon Technologies Inc has raised $55M in disclosed capital across 10 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $21M on 2024-01-31.
Most recent recorded round closed around 2025-05-23.
Valuation (modeled)modeled
Provath models Dilon Technologies Inc at approximately $39M (range $16M–$59M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.51× the median modeled value of Series B Biotechnology companies in 2025–2027 (94 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 13 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 4.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 83% of Biotechnology peers (4293 compared).
Modeled value ranks above 40% of those peers.
Closest niche peers: MarvelBiome, Inc., Iantrek, Inc., Dualitas Therapeutics, Inc., Antares Therapeutics, Inc., OrthoBio Therapeutics, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.